There are 2789 resources available
234P - Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3)
Presenter: Hope Rugo
Session: ePoster Display
204P - Predictive factors for relapse in triple-negative breast cancer (TNBC) patients without pathologic complete response (PCR)
Presenter: Marta Venturelli
Session: ePoster Display
205P - Immunomodulation in early triple-negative breast cancer (TNBC): Analysis of soluble markers as predictive biomarkers to neoadjuvant chemotherapy in TNBC
Presenter: Martin Nunez Abad
Session: ePoster Display
206P - Disease behavior and treatment response of special histological types of triple-negative breast cancer
Presenter: Renata Bonadio
Session: ePoster Display
207P - Outcomes of patients with triple-negative breast cancer following neoadjuvant chemotherapy with anthracycline and taxane-based regimens plus carboplatin
Presenter: Bryan Vaca Cartagena
Session: ePoster Display
208P - ARB: Phase II window of opportunity study of preoperative treatment with enzalutamide in ER+ve and TNBC
Presenter: Peter Schmid
Session: ePoster Display
209P - Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors
Presenter: Samuel Klempner
Session: ePoster Display
210P - TACH101, a first-in-class KDM4 inhibitor for treatment of triple-negative breast cancer
Presenter: Frank Perabo
Session: ePoster Display
211P - Genetic and immunologic characteristics in Chinese breast patients with different HER2 mutation types
Presenter: Hui Cao
Session: ePoster Display
212P - HER2-low breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment
Presenter: Federica Miglietta
Session: ePoster Display